June 3, 2015. Radium-223, brand name Xofigo (formerly Alpharadin), is an FDA approved intravenous injectable treatment for painful bone metastases in men with castration-resistant prostate cancer (CRPC). The drug Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. Radium-223 is taken by intravenous injection once a month (every four weeks) for up to six months. Radium-223 received priority review two years ago based on its ability to extend Overall Survival as shown in its Phase 3 trial. ...continue reading "Radium-223 linked to longer overall survival in patients with castration-resistant prostate cancer with bone metastases"
May 18, 2015— AUA, New Orleans. A study of medical records of nearly 10,000 patients with prostate cancer shows that active surveillance (the updated form of watchful waiting) is suitable for most men with low-risk disease. Twelve to 15 years after diagnosis, these men are no more likely to die of prostate cancer than of other conditions and diseases. By contrast, the study shows, to avoid dying of prostate cancer men with high-risk disease may require aggressive "multimodal treatment" including surgery. ...continue reading "Active Surveillance For Low-Risk Prostate Cancer Does Not Shorten Life"
June 2, 2015. Primary androgen deprivation therapy for localized prostate cancer increases diabetes risk by up to 60 per cent, particularly in men under 70 years of age, according to research published in the June issue of The Journal of Urology.
"As the benefits of primary androgen deprivation therapy for localized prostate cancer are controversial," the authors say, "and most prostate cancer survivors are of advanced age with comorbidities, it is important to determine if primary androgen deprivation therapy increases the risk of diabetes and to determine the susceptibility factors." ...continue reading "Diabetes A Risk For Men Treated With Androgen Deprivation for Localized Prostate Cancer"
Already available, designed to reduce unneeded biopsies
May 18, 2015 ANN ARBOR, Mich. — A new urine-based test improves prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.
The test, developed at the University of Michigan Comprehensive Cancer Center, is called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, T2:ERG and PCA3, both of which can be detected through a urine sample. The test has been available clinically since September 2013. ...continue reading "Urine-Based Test Improves on PSA for Detecting Prostate Cancer"
May help determine specialized treatment
PSA Rising via TORONTO, Canada – May 27, 2015 – Prostate cancer researchers in Canada have drawn a molecular portrait that provides the first complete picture of localized, multi-focal disease within the prostate and also unveils a new gene subgroup driving it.
For cancer patients, a brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments.
Brad Behnke, associate professor of exercise physiology at Kansas State University has shown together with colleagues that moderate exercise on a regular basis enhances tumor oxygenation. Getting more oxygen into a tumor may improve treatments in cancer patients. ...continue reading "Moderate Exercise May Make Cancer Treatments More Effective"
In mouse models immune cell manipulation plus chemotherapy achieves prostate cancer remission where chemotherapy alone fails
Blocking or removing immune-suppressing cells , researchers at the University of California, San Diego School of Medicine have found, allows a special type of chemotherapy — and the immune cells it activates — to destroy prostate tumors.
This combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer. ...continue reading "Targeting B Cells to Tackle Immune System Suppression in High Risk Prostate Cancers"
This chart shows the National Cancer Center Network Guidelines, 2014, for use of the PSA test and Digital Rectal Exam (DRE) for early detection of prostate cancer. Recommendations for men over age 70 are below the chart.